echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA blockbuster drug approval plan in October 2021

    FDA blockbuster drug approval plan in October 2021

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    As of September this year, the US FDA has approved a total of 40 innovative drugs, compared with 40 in the same period last year and 53 in the whole year of last year


    ——Takeda's tyrosine kinase inhibitor Exkivity is the first oral therapy to treat non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation;

    -Tivdak, the tissue factor (TF) targeted drug of Seattle Genetics, is the first antibody-conjugated drug (ADC) for the treatment of cervical cancer;

    -AbbVie Qulipta is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for the preventive treatment of migraine;

    --Mirum Pharmaceuticals' oral ASBT inhibitor Livmarli is the first drug to treat cholestatic pruritus in patients with Alagil syndrome (ALGS)


    Entering October, a number of drugs will usher in an important review decision by the FDA


    Reference source: Biotech Stocks Facing FDA Decision In October 2021

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.